Your selection

Innovation / 12.05.2026
Eckert & Ziegler with a Successful Start to the Year. 2026 Forecast Confirmed.

1st Quarter 2026:

  • Sales of €72.9 million (previous year: €68.2 million)
  • EBIT before special items of €16.0 million (previous year: €16.2 million)
  • Net income of €10.4 Mio.  (previous year: €9.7 million)

 Forecast 2026:

  • Sales of around €320 million (confirmed)
  • EBIT before special items of around €80 million (confirmed) 
     

Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) increased its sales in the first quarter of 2026 by 7% to €72.9 million compared with the same period last year. Due to a slightly weaker product mix in the Isotope Products segment during the first two months of the year, adjusted Group EBIT decreased by 2% to €16.0 million. Net income increased by 7% to €10.4 million, or €0.17 per share.

Sales in the Medical segment were significantly higher in the first three months of the year at €41.5 million compared to the previous year (€34.4 million). The pharmaceutical radioisotope business remains the most important revenue driver. In particular, the development of sales of generators and in the Contract Manufacturing & Development (CDMO) segment is worth noting.

The Isotope Products segment generated sales of €31.5 million, which was €2.3 million, or approximately 7%, lower than in the first three months of the previous year. A strong fourth quarter of 2025 was followed by a subdued start to the year, which regained significant momentum in March.

The forecast for fiscal year 2026, published on 26 March 2026, remains unchanged. The Executive Board continues to anticipate revenue of approximately €320 million and adjusted EBIT of approximately €80 million.

The complete quarterly report can be viewed here: https://www.ezag.com/Q12026en
 

About Eckert & Ziegler.
Eckert & Ziegler SE with more than 1,000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Overview News

News Buch Berlin

ERC Advanced Grants awarded to two Berlin researchers

Uwe Ohler and Gaetano Gargiulo have been awarded prestigious ERC Advanced Grants. With funding of €2.5 million each, they will spend the next five years investigating how protein synthesis is regulate...

more ...

Eckert & Ziegler and DC Pharma Open Commercial Medical Isotope Production Site in Jintan

Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) today officially opened the new medical isotope production site of its joint venture Qi Kang Medical Technology (Changzhou) Co., Ltd. (QKM) in the Jinta...

more ...

Berlin honors outstanding deep-tech companies—including MyoPax

This year, for the first time, a Deep Tech Award was presented in the Bio & Health Tech category. The winner is MyoPax, a spin-off of the Max Delbrück Center and Charité.

more ...

Events Buch Berlin

27.08.2026, 10:00
CRISPR/Cas: Grundlagen und praktische Anwendung (Verschoben vom 4. Juni auf 27. August)

Der Crashkurs für Einsteiger*innen vermittelt die Grundlagen der CRISPR/Cas Technologie. Die Teilnehmer*innen sollen in die Lage versetzt werden, CRISPR/Cas Experimente selbständig zu planen und durch...

more ...

22.09.2026, 09:00
GMP Biotech Summer School

Knowing and applying the Good Manufacturing Practice (GMP) regulations is one of the key elements in the manufacture of medicinal products for clinical trials and on an industrial level.

more ...

09.11.2026, 09:00
Fachkraft für Molekularbiologie

Elftägiges Intensivseminar der Berlin BioScience Academy. Es rmittelt Grundlagenwissen zu den wichtigsten Labormethoden der modernen Molekularbiologie und vermittelt Einblicke in die klinische Forschu...

more ...

This website is supported by: